> ## Content Index > Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt > Use this file to discover other available public pages before exploring further. # Moderna Seeks Second COVID-19 Booster for All Adults as U.S. Weighs How Long Third-Dose Protection Lasts - URL: https://www.theamericanquorum.com/taq-historical-2022-03-19-healthcare/ - Published: 2022-03-20T03:59:00.000Z - Updated: 2022-03-20T03:59:00.000Z - Description: Moderna has asked FDA to authorize a fourth COVID-19 vaccine dose for all adults, two days after Pfizer sought a second booster for people 65 and older, intensifying debate over waning protection. - Author: Kenneth R. Deans Jr. - Tags: Healthcare, #Import 2026-08-31 10:27 Moderna has asked the Food and Drug Administration to authorize a second COVID-19 booster dose for all adults, broadening a national debate over how long protection from a third dose lasts and which Americans might benefit from another shot. The request, announced Thursday, would allow adults 18 and older who have already received an initial booster to receive a fourth dose of Moderna’s mRNA vaccine. The [American Hospital Association reported](https://www.aha.org/news/news/2022-03-18-moderna-asks-fda-authorize-second-booster-all-adults?ref=theamericanquorum.com) that Moderna framed the broad authorization as a way to give the CDC and clinicians flexibility to decide who should receive an additional dose based on age, health conditions and individual risk. The submission came only two days after Pfizer and BioNTech asked the FDA to authorize a second booster for adults 65 and older. Together, the requests place federal regulators at the center of a new question in pandemic policy: whether additional boosters should become a routine tool and, if so, for whom. ## Moderna asks for broader eligibility than Pfizer Moderna’s proposal covers all adults rather than only older people. The company says the wide authorization would not necessarily mean every adult should immediately receive another dose; instead, it would allow public-health authorities and healthcare providers to target use according to risk. The [Washington Post reported](https://www.washingtonpost.com/health/2022/03/17/moderna-second-coronavirus-booster-fda/?ref=theamericanquorum.com) that the company based its request partly on evidence from the United States and Israel showing changes in vaccine effectiveness during the Omicron period. Protection against infection appears to decline faster than protection against severe illness, leaving policymakers to decide which outcome should drive booster recommendations. [NPR reporting](https://www.kpbs.org/news/national/2022/03/17/moderna-seeks-approval-for-second-covid-19-booster-shot-for-adults?ref=theamericanquorum.com) emphasized that Moderna’s application is substantially broader than Pfizer’s and arrives while U.S. cases are low compared with the winter Omicron peak. That timing makes the decision less about responding to an immediate national surge and more about preparing for future transmission or a new variant. ## Pfizer seeks a second booster for older adults Pfizer and BioNTech submitted their own application Tuesday for people 65 and older. In a [company announcement](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization?ref=theamericanquorum.com), the partners said the request was supported by real-world data from Israel collected while Omicron was circulating. The narrower age threshold reflects the much higher risk of severe COVID-19 among older adults and the possibility that any decline in protection against hospitalization could have the greatest consequences in that population. Older people were among the first Americans to receive primary vaccination and boosters, so they also have some of the longest intervals since their most recent dose. Federal regulators must distinguish between waning protection against any symptomatic infection and waning protection against hospitalization and death. A vaccine can become less effective at preventing mild breakthrough cases while retaining substantial value against severe disease. ## Evidence on booster durability is still developing CDC data have already shown that booster protection is not static. Earlier this year, the agency shortened the interval for a Moderna booster from six months to five months after the primary series. The [January recommendation](https://archive.cdc.gov/www%5Fcdc%5Fgov/media/releases/2022/s0107-moderna-booster.html?ref=theamericanquorum.com) reflected accumulating evidence that an additional dose improves protection during the Omicron wave. Safety monitoring also continues as booster use expands. A CDC [MMWR report](https://www.cdc.gov/mmwr/volumes/71/wr/mm7109e2.htm?ref=theamericanquorum.com) released this month found that booster reactions among adolescents were generally mild to moderate and transient, adding to the safety evidence for additional mRNA doses even though the study does not answer the separate question of a fourth dose in adults. The FDA and CDC will need to assess data from Israel, clinical studies, U.S. effectiveness monitoring and the trajectory of the virus. The agencies must also decide whether the benefit of another dose is large enough to justify recommending it broadly or whether it should be focused on older and medically vulnerable populations. ## Future variants complicate the timing Both Moderna and Pfizer are working on updated vaccine formulations, including candidates designed around Omicron. That creates a strategic question: whether to give another dose of the current vaccine now, wait for a variant-specific product, or reserve additional boosting for a period closer to an expected seasonal increase. The answer may differ by risk group. An older adult or person with significant immune compromise may gain meaningful near-term benefit from an additional dose, while a healthy younger adult may retain strong protection against severe disease from the current three-dose series. Supply is not the only constraint. Public acceptance of repeated boosters could decline if recommendations change frequently or if the benefit is framed unclearly. Public-health agencies will need to explain whether a fourth dose is intended primarily to prevent infection, severe disease or both. The debate also arrives as the federal government warns that pandemic-response funding is running low. Congress removed $15.6 billion in COVID-19 aid from the recent omnibus spending bill, creating uncertainty about future government purchases of vaccines, treatments and tests. ## Regulators now face a risk-based decision The emerging booster question is less binary than earlier vaccine decisions. The primary series and first booster have strong evidence of protection against severe outcomes. A second booster may provide an additional layer of protection, but the size and duration of that benefit may vary substantially by age, prior infection, immune status and time since the last dose. Moderna’s request gives the FDA authority to consider a broad label, while Pfizer’s gives the agency a narrower option focused on seniors. The CDC would then determine how any authorized dose should be recommended in clinical practice. The submissions signal that COVID-19 vaccination is entering a more individualized phase. Rather than a single schedule for nearly everyone, future recommendations may increasingly depend on vulnerability and changing viral conditions. The immediate decision on second boosters will be an early test of how regulators manage that transition while the evidence is still developing.